Contact Us

Overview

Technology

OxStem has formed a team with decades of experience in medicinal medicine. They are brilliantly aligning to design drugs that can “program resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.”

OxStem Oncology is developing a universal differentiation therapy targeting hematological malignancies, focusing on acute myeloid leukemia (AML). The new medicine is expected to normalize hemopoiesis by differentiating leukemic myeloblasts resulting in complete durable remission for AML patients irrespective of their mutation status.

OxStem Ocular aims to identify new classes of drugs that can stimulate retinal precursor cells in patients with retinopathies such as dry age-related macular degeneration (dAMD) and retinitis pigmentosa. These new medicines are expected to induce retinal repair resulting in the restoration of vision.

OxStem Neuro has identified small molecules that can stimulate neural stem cells in situ resulting in neurogenesis and enhancement of cognitive function. As neurogenesis is compromised during aging and in neurodegenerative diseases such as Alzheimer’s, induction of neurogenesis represents a new therapeutic principle for such conditions.

OxStem Cardio aims to identify new classes of drugs that can stimulate cardiovascular cell regeneration from the activated epicardium and coronary lymphatic vessels. This is expected to restore lost tissue and improve cardiac function in cardiac disease conditions such as myocardial infarction.

OxStem Beta will develop therapeutics which stimulate regeneration of insulin-producing beta cells using small molecules diabetes.

OxStem Immuno’s underpinning technology aims to help stimulate tissue repair in chronic inflammation. The aim is to develop small molecules capable of switching macrophages from an infection-fighting anti-inflammatory phenotype, to treat chronic wounds such as diabetic foot ulcers.

Screening